On Nov. 5, 2021, Chugai Pharmaceutical, announced that it had obtained approval from the Ministry of Health, Labour and Welfare for the anti-SARS-CoV-2 monoclonal antibody RONAPREVE [generic name: casirivimab (genetical recombination) /imdevimab (genetical recombination)] for the additional indication of the prevention of smptomatic SARS-CoV-2 infection (COVID-19).